| Recruiting | An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent NCT06447103 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Unknown | Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites NCT04267575 | Jerome Canady, M.D. | N/A |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Terminated | Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer NCT03260504 | University of Washington | Phase 1 |
| Completed | Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278 | Rutgers, The State University of New Jersey | Phase 1 |
| Completed | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190 | Stanford University | N/A |
| Active Not Recruiting | Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer NCT03092856 | University of Southern California | Phase 2 |
| Completed | Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer NCT02899078 | University of California, Davis | Phase 1 / Phase 2 |
| Completed | Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With NCT02944617 | City of Hope Medical Center | N/A |
| Terminated | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Pro NCT02650635 | Mayo Clinic | Phase 1 |
| Completed | Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations NCT02646319 | Mayo Clinic | EARLY_Phase 1 |
| Completed | 18F-FSPG PET/CT for Cancer Patients on Therapy NCT02599194 | Andrei Iagaru | Phase 2 |
| Terminated | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer NCT02542202 | University of Chicago | N/A |
| Unknown | Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors NCT02526511 | Rutgers, The State University of New Jersey | N/A |
| Completed | APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Me NCT02166255 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kid NCT02273752 | Emory University | Phase 2 |
| Terminated | Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer NCT01943188 | Stanford University | Phase 1 |
| Completed | Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointe NCT01846520 | City of Hope Medical Center | N/A |
| Completed | Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery NCT01892930 | Roswell Park Cancer Institute | N/A |
| Completed | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer NCT01767636 | Mayo Clinic | Phase 2 |
| Completed | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis NCT01806675 | Sanjiv Sam Gambhir | Phase 1 / Phase 2 |
| Completed | Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Can NCT01727076 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer NCT01826877 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cance NCT01684397 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer NCT01727089 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer NCT01740154 | Case Comprehensive Cancer Center | N/A |
| Completed | Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Ki NCT01688973 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patien NCT01599832 | University of Chicago | N/A |
| Completed | Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by NCT01548482 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer NCT01157091 | City of Hope Medical Center | Phase 2 |
| Completed | A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcino NCT01265368 | Mologen AG | Phase 1 / Phase 2 |
| Completed | Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies NCT01243359 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer NCT01158222 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanc NCT01198184 | National Cancer Institute (NCI) | Phase 1 |
| Completed | A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Grow NCT01141569 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Completed | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does N NCT01582009 | Roswell Park Cancer Institute | Phase 1 / Phase 2 |
| Completed | Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastat NCT01061411 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung NCT00937482 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced NCT01026337 | Abramson Cancer Center at Penn Medicine | — |
| Terminated | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer NCT00684996 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tu NCT00499135 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer NCT00408902 | National Cancer Institute (NCI) | Phase 2 |
| Completed | AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery NCT00348699 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors NCT00335556 | Children's Oncology Group | Phase 2 |
| Completed | Ispinesib in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00354250 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer NCT00324740 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer NCT00303862 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery NCT01158534 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer NCT00324870 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer NCT00126659 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cediranib Maleate in Treating Patients With Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Su NCT00227760 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vorinostat in Treating Patients With Kidney Cancer NCT00278395 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Sta NCT00217542 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Ixabepilone in Treating Patients With Metastatic, Recurrent, or Unresectable Kidney Cancer NCT00182702 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney NCT00126594 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer NCT00126503 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00112840 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer NCT00126490 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors NCT00112476 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidne NCT00101348 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors NCT00655655 | Mayo Clinic | Phase 1 |
| Terminated | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer NCT00098618 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer NCT00101114 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fluorouracil and Low-Dose Suramin as Chemosensitization in Treating Patients With Metastatic Renal Cell (Kidne NCT00083109 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Mali NCT00078858 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer NCT00059813 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer NCT00060307 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer NCT00032188 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment NCT00009919 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer NCT00006486 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transpl NCT00005851 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients Wi NCT00005799 | Fred Hutchinson Cancer Center | N/A |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer NCT00019539 | National Cancer Institute (NCI) | Phase 2 |
| Completed | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer NCT00019396 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer NCT00040989 | Jonsson Comprehensive Cancer Center | Phase 2 |